Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Old and New Anti-Obesity Drugs Publisher



Dodangeh S1 ; Hasaniranjbar S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Diabetes and Metabolic Disorders Published:2025


Abstract

Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality. It is necessary to approach obesity with a comprehensive treatment plan, which may involve lifestyle modifications (diet, exercise, and behavioral therapy) and pharmacological interventions. This article provides an overview of the mechanisms of action, efficacy, and safety of available long-term anti-obesity drugs and introduces other potential agents under investigation. © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024.
Related Docs
View other Related Docs
1. The Effects of Bupropion Alone and Combined With Naltrexone on Blood Pressure and Crp Concentration: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials, European Journal of Clinical Investigation (2024)
2. Changes in Lipid Profile and Glucose Metabolism Following Administration of Bupropion Alone or in Combination With Naltrexone: A Systematic Review and Meta-Regression Analysis, European Journal of Clinical Investigation (2024)
3. The Blood Pressure-Lowering Property of Subcutaneous Semaglutide: A Systematic Review, Meta-Analysis, and Meta-Regression, Journal of Endocrinological Investigation (2025)
4. The Effects of Bupropion Alone and Combined With Naltrexone on Weight Loss: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials, Diabetology and Metabolic Syndrome (2024)
5. The Pathophysiological Associations Between Obesity, Nafld, and Atherosclerotic Cardiovascular Diseases, Hormone and Metabolic Research (2024)
6. National-Level and State-Level Prevalence of Overweight and Obesity Among Children, Adolescents, and Adults in the Usa, 1990–2021, and Forecasts up to 2050, The Lancet (2024)
7. Weight Loss Breaks the Bond Between Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: A Clinical and Epidemiological Perspective, Obesity Reviews (2023)
8. Suicide and Self-Harm Events With Glp-1 Receptor Agonists in Adults With Diabetes or Obesity a Systematic Review and Meta-Analysis, JAMA Psychiatry (2025)
Experts (# of related papers)
View all Related Experts
Pejman Rohani (3)
Shekoufeh Nikfar (1)
Other Related Docs
9. A Comment On: “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide”, Journal of Diabetes and Metabolic Disorders (2024)
10. The Effects of Subcutaneous Tirzepatide on Obesity and Overweight: A Systematic Review and Meta‐Regression Analysis of Randomized Controlled Trials, Frontiers in Endocrinology (2023)
11. The Effects of Gut Microbiome Manipulation on Glycemic Indices in Patients With Non-Alcoholic Fatty Liver Disease: A Comprehensive Umbrella Review, Nutrition and Diabetes (2024)
12. Tirzepatide Outcompetes Long-Acting Insulin in Managing Type 2 Diabetes: A Meta-Analysis of Three Phase 3 Randomized Controlled Trials, International Journal of Obesity (2024)